Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health, Inc. (NASDAQ:JAGX) announced the successful issuance of a $6 million secured promissory note to Streeterville Capital, LLC. The financing supports the development of lechlemer, aimed at treating diarrhea and dehydration in cholera patients. The investor holds a right to 18% of gross proceeds from a potential tropical disease priority review voucher (TDPRV). This program incentivizes drug development for neglected diseases and has seen previous vouchers sold for up to $350 million. Napo Pharmaceuticals, Jaguar's subsidiary, is conducting ongoing preclinical studies for lechlemer, which is derived from the Croton lechleri tree.

Jaguar Health, Inc. (NASDAQ:JAGX) has released a recap of its January 14, 2021 investor webcast and provided a replay link due to high participation. Key highlights include plans to pursue conditional marketing authorization in Europe for crofelemer, aimed at treating 'long-hauler' COVID-19 symptoms. The company announced a securities purchase agreement, raising approximately $15 million, and a $6 million agreement related to Napo's lechlemer drug candidate. Jaguar also discussed establishing Napo EU in Italy, targeting additional value from potential licensing arrangements.

Jaguar Health announced a $6 million non-dilutive financing arrangement involving the sale of partial rights to a Tropical Disease Priority Review Voucher (TDPRV). This financing aims to support the clinical development of lechlemer for alleviating diarrhea in cholera patients. The TDPRV, previously valued between $67 million and $350 million, incentivizes drug development for neglected and rare diseases. The company has established that funds from this deal will fully cover the lechlemer clinical program, which is expected to advance clinical trials following positive initial studies.

Jaguar Health, Inc. (NASDAQ:JAGX) has entered a securities purchase agreement with two institutional investors for the sale of 4,437,870 shares of common stock at $3.38 per share, aiming for gross proceeds of approximately $15 million. The offering, scheduled to close around January 15, 2021, is executed under a shelf registration statement effective since September 23, 2020. Ladenburg Thalmann acts as the exclusive placement agent. The funds will be used to support the company's development of plant-based medicines for GI distress, specifically targeting chronic diarrhea.

Jaguar Health, Inc. (NASDAQ:JAGX) announces that CEO Lisa Conte will present at the H.C. Wainwright BIOCONNECT 2021 virtual conference from January 11-14, 2021, with a presentation available on-demand. Additionally, Conte will speak at the NobleCon17 on January 19, 2021, at 4:30 PM Eastern Time. An investor webcast will also be hosted on January 14, 2021, at 11:30 AM Eastern Time. The company plans to explore conditional marketing for crofelemer, targeting post-COVID-19 recovery patients. More details and registration links are provided.

Jaguar Health (NASDAQ:JAGX) is exploring conditional marketing authorization in Europe for crofelemer, targeting symptomatic relief of inflammatory diarrhea in long-hauler COVID-19 patients. The company plans meetings with the EMA, Swissmedic, and MHRA to facilitate this. With indications that up to 70 million people in Europe may suffer from gastrointestinal distress post-COVID-19, Jaguar aims to address this growing need. Additionally, an investor webcast is scheduled for January 14 to discuss updates and funding strategies for this initiative.

Jaguar Health, Inc. (NASDAQ:JAGX) announced a 28-day preclinical safety and toxicity study for its plant-based drug candidate lechlemer, aimed at treating diarrhea caused by cholera, starting January 6, 2021. This study supports the upcoming Investigational New Drug (IND) application and follows prior studies in rats and shorter dog studies. The company seeks a priority review voucher from the FDA, which could enhance its market potential. Cholera remains a significant health issue, with millions of cases annually, underlining the urgency of developing effective treatments.

Jaguar Health, Inc. (NASDAQ:JAGX) has secured a $6 million non-dilutive royalty financing agreement with a secured lender. The funds will be designated for regulatory activities linked to the development pipeline, particularly for the pivotal clinical trial of Mytesi (crofelemer) aimed at cancer therapy-related diarrhea (CTD). Notably, no royalty payments are required for 18 to 24 months. CEO Lisa Conte highlighted that the growth in Mytesi's sales for HIV-related diarrhea underpins this financial opportunity. This follows a previous $6 million royalty transaction with the same lender in October 2020.

Jaguar Health announced the approval of two proposals during its Special Meeting held on December 22, 2020. The company will not implement a reverse stock split at this time. A key focus is the potential merger of Napo EU with the SPAC targeting €20-50 million investment, aimed at developing crofelemer for long-hauler syndrome gastrointestinal distress in Europe. An investor webinar is scheduled for December 23, 2020, to discuss the urgent need for regulatory approval following the emergence of a new COVID-19 strain. CEO Lisa Conte expressed optimism for the company's future.